Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EE Mitogen-activated protein kinase (MEK) inhibitors
L01EE05 Mirdametinib
D11675 Mirdametinib (USAN) <US>
Drug groups [BR:br08330]
Antineoplastic
DG03137 MEK inhibitor
D11675 Mirdametinib
Metabolizing enzyme substrate
DG02970 CES substrate
D11675 Mirdametinib
DG02924 UGT substrate
DG03335 UGT1A6 substrate
D11675 Mirdametinib
DG03190 UGT2B7 substrate
D11675 Mirdametinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
STE group
MAP2K (MEK)
D11675 Mirdametinib (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11675
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11675
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11675